Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22914917 | 0.83 | ALDH1A1 (0.42) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL8388461 | 0.83 | ALDH1A1 (0.42) | KDM4ECA2CA1MMP1MMP2 | |
| Carbamic Acid SCHEMBL28155281 | 0.75 | TPMT (0.60) | KDM4ETPMTPRSS1PRSS2PRSS3 | |
| SCHEMBL17389037 | 0.74 | KDM4E (0.43) | KDM4ECA2CA1MMP1MMP2 | |
| Carbamic Acid SCHEMBL28131089 | 0.73 | TPMT (0.57) | KDM4EL3MBTL1TPMTPRSS1PRSS2 | |
| SCHEMBL394947 | 0.73 | CA2 (0.39) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL21993465 | 0.73 | ALDH1A1 (0.48) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL394948 | 0.73 | SELL (0.46) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL16706958 | 0.71 | ELANE (0.42) | KDM4ECA2CA1MMP1MMP2 | |
| SCHEMBL18957772 | 0.70 | RAPGEF4 (0.39) | KDM4ECA2CA1MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117304191-A | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-7674791-B2 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1615931-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092177-A1 | TRIAZOLOPYRAZINES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KDM4E 4656/4885CA2 2216/4885CA1 3550/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | KDM4E 4656/4885CA2 2216/4885CA1 3550/4885 |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | KDM4E 4656/4885CA2 2216/4885CA1 3550/4885 |
| US-20070010520-A1 | Triazolopyrazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | KDM4E 1661/4885CA2 1823/4885CA1 2546/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | KDM4E 4656/4885CA2 2216/4885CA1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.